Basal Cell Carcinoma Clinical Trial
Official title:
A Phase 2A Study to Assess the Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor in the Treatment of Multiple Low Risk Basal Cell Carcinomas in Sporadic or Basal Cell Nevus Syndrome Patients
Verified date | April 2024 |
Source | Ascend Biopharmaceuticals Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary objectives are to: 1. Evaluate the safety and tolerability of intralesional ASN-002 when administered in combination with oral vismodegib in patients with Basal Cell Carcinomas (BCC)s; 2. Evaluate the efficacy of intralesional ASN-002 in target tumours when administered in combination with oral vismodegib in patients with BCCs. The secondary objective is to: 1) Evaluate the efficacy of intralesional ASN-002 in non-target tumours when administered in combination with oral vismodegib in patients with BCCs. The exploratory objective is to: 1) Evaluate immunological biomarkers during the course of treatment.
Status | Completed |
Enrollment | 21 |
Est. completion date | February 14, 2024 |
Est. primary completion date | February 14, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Histologically confirmed previously untreated, BCC (nodular and superficial), 5-20 mm in maximum diameter, per the selection criteria for study BCC tumours. A punch biopsy (refer to study procedure manual for biopsy size selection) from the thickest part of all the target tumours is required for histological confirmation of BCC and to exclude BCC non-eligible subtypes. Note: If a patient has mix of nodular and superficial BCC tumours, at least one target tumour should be a nodular BCC. 2. Removal of < 25% of the area of each biopsied tumour by initial biopsy performed 1-12 weeks before Day 1. If the initial biopsy was performed >8 weeks prior to screening, the investigator may re-biopsy the tumour, provided not > 25% of the area of the original tumour is removed. Non-study tumours may be resected or treated at the discretion of the Investigator prior to study entry or if they develop during the study. 3. Hedgehog pathway inhibitor treatment naïve. 4. Acceptable general health as determined by the investigator, i.e. no serious or active medical or psychiatric illness or recreational or therapeutic drug or alcohol use that, in the opinion of the Investigator, would interfere with treatment, assessment or compliance with the protocol, ability to provide informed consent, or patient safety. 5. 18 years of age or older. 6. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2. 7. Screening laboratory values as follows: 1. Neutrophil count > 1500/mm3 2. Haemoglobin > 9 g/dL 3. Platelet count >100,000/mm3 4. Prothrombin INR < 1.5 5. Total bilirubin < 1.5 X upper limit of normal (ULN), except in the case of known Gilbert's syndrome 6. Aspartate transaminase (AST), alanine transaminase (ALT) or alkaline phosphatase (ALP) < 2X ULN 7. Creatinine < 1.5 X upper limit of normal (ULN) 8. Female patients who are documented infertile, postmenopausal for at least 1 year, surgically sterile or using acceptable and highly effective birth control for the duration of the study and for at least 3 months after last administration of the study treatments. 9. Male patients with female partners of child bearing potential, agreement to use two adequate contraception methods while being on vismodegib and for 3 months of completion. agreement not to donate semen for 3 months after completion of vismodegib. 10. Written informed consent prior to initiation of study-specified procedures. 11. Able and willing to comply with all study requirements, including surgical removal of tumour/tumour site at completion of study. 12. Baseline tissue sample adequate for determination of histological or other biomarkers. Exclusion Criteria 1. Known or suspected metastatic disease or other active, invasive malignancy. 2. Female patients of childbearing potential who are lactating or pregnant (negative serum pregnancy test needed prior to dosing). 3. Clinically active or uncontrolled skin disease or tattoos that would interfere with evaluation of the area surrounding the target tumour (e.g. eczema, unstable psoriasis, xeroderma pigmentosa). 4. Known history of sensitivity to any of the ingredients in ASN-002 and any Hh pathway inhibitors. 5. Immunocompromised (e.g. known Hepatitis B or C infection, HIV infection) or receiving or expected to receive an immunomodulating agent (including immunosuppressive agents, cytotoxic drugs, biological agents, immunoglobulins, interferon or other immune or cytokine-based therapies. Use of inhaled or oral corticosteroids at doses higher than physiological replacement doses is an exclusion criterion). 6. Has received or is expected to receive treatment with psoralen plus UVA or UVB therapy within 6 months of the Screening visit. 7. Any prior systemic anti-tumour therapy or local treatment for target tumours prior to first dose. 8. History of immunological disorder, severe allergic reaction, moderate or severe asthma or known history of anaphylaxis or any other serious adverse reactions to any medication. 9. Any experimental or investigational agents within one month of first ASN-002 injection. 10. Any prior exposure to TG1041, TG1042 (ASN-002), any other adenoviral-based experimental agent, or any form of gene therapy within 6 months of first dose of vismodegib in the study. 11. Any prior exposure to vismodegib or any other Hh inhibitor within 6 months of first dose in the study. 12. Current therapy with any medications recognized to cause rhabdomyolysis or a prior history of rhabdomyolysis. |
Country | Name | City | State |
---|---|---|---|
Australia | Central Brisbane Dermatology | Brisbane | Queensland |
Australia | Princess Alexandra Hospital | Brisbane | Queensland |
Australia | Veracity Clinical Research | Brisbane | Queensland |
Australia | Royal Melbourne Hospital | Melbourne | Victoria |
Australia | Sinclair Dermatology | Melbourne | Victoria |
Australia | Burswood Dermatology | Perth | Western Australia |
Australia | Sunshine Coast University Hospital | Sunshine Coast | Queensland |
Lead Sponsor | Collaborator |
---|---|
Ascend Biopharmaceuticals Ltd |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of ASN-002 related Adverse Events in patients with previously untreated nBCC | Incidence of Adverse Adverse events will be monitored | Participants will be followed up to 6 months | |
Primary | Microscopic clearance of the injected Target basal cell carcinoma. | Histological clearance (HC) will be defined as the absence of detectable evidence of BCC tumor cell nests in serial histological samples as determined by central pathology review. | Microscopic examinations of sample collected at weeks 25-33 after the first dose. | |
Secondary | Microscopic clearance of the injected Non-Target basal cell carcinoma. | Histological clearance (HC) will be defined as the absence of detectable evidence of BCC tumor cell nests in serial histological samples as determined by central pathology review. | Microscopic examinations of sample collected at weeks 25-33 after the first dose. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04552990 -
Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma
|
Phase 2 | |
Completed |
NCT04229277 -
Fast Track Diagnosis of Skin Cancer by Advanced Imaging
|
N/A | |
Completed |
NCT05608902 -
Structural Description of Skin Biopsies With Dynamic Full-field Optical Coherence Tomography on Suspected Basal Cell Carcinoma Lesions, a Pilot Study (DOCTOBA)
|
||
Completed |
NCT05077033 -
Intratumoral phIL12 GET
|
Phase 1 | |
Active, not recruiting |
NCT04928222 -
Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04929535 -
Hydrogen Peroxide Trial to Investigate the Efficacy of 30%H2O2 as a Topical Application Before Definitive Treatment
|
Phase 2 | |
Completed |
NCT02662244 -
Long-pulsed 1064 nm Nd:YAG Laser Treatment of Basal Cell Carcinoma
|
N/A | |
Completed |
NCT00959647 -
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
|
Phase 2 | |
Completed |
NCT00793169 -
Serum Concentration of Lidocaine After Local Injection During Mohs Micrographic Surgery
|
||
Completed |
NCT00586040 -
Photochemical Tissue Bonding
|
Phase 2 | |
Completed |
NCT00473343 -
Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma
|
Phase 3 | |
Active, not recruiting |
NCT06024629 -
cOCT Versus LC-OCT for Diagnosing Basal Cell Carcinoma: a Diagnostic Cohort Study
|
||
Not yet recruiting |
NCT05324202 -
New Imaging Procedures and Therapeutic Approach in Basal Cell Carcinoma Management
|
N/A | |
Withdrawn |
NCT04099446 -
A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer
|
||
Completed |
NCT02902822 -
Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo
|
N/A | |
Completed |
NCT01208831 -
An East Asian Study of LDE225
|
Phase 1 | |
Completed |
NCT01201915 -
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma
|
Phase 2 | |
Completed |
NCT01260987 -
Fractional CO2 Laser Assisted Photodynamic Therapy
|
Phase 2/Phase 3 | |
Completed |
NCT01014819 -
A Clinical Trial of Dermacorder for Detecting Malignant Skin Lesions
|
N/A | |
Completed |
NCT00472043 -
PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Call Carcinoma
|
Phase 3 |